Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRNB2 | P17787 | 1/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.41 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | IKBKB | O14920 | 1/20 | 0.38 |
| ▸ | HRH4 | Q9H3N8 | 4/20 | 0.37 |
| ▸ | ACVR1 | Q04771 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.37 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.36 |
| ▸ | PRKD1 | Q15139 | 1/20 | 0.36 |
| ▸ | PRKD2 | Q9BZL6 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL874422 | 0.82 | HRH1 (0.41) | HRH1USP2SMN1; SMN2TDP1HTR2C | |
| SCHEMBL4060441 | 0.79 | HTR2C (0.43) | CHRNB2CHRNA4HTR2C | |
| Hydrochloric Acid SCHEMBL18282483 | 0.78 | KDM4E (0.38) | CHRNB2CHRNA4IRAK4IKBKBACVR1 | |
| SCHEMBL2339894 | 0.77 | HRH1 (0.39) | HRH1USP2SMN1; SMN2TDP1HTR2C | |
| SCHEMBL2347424 | 0.77 | KDM4E (0.56) | — | |
| SCHEMBL2347716 | 0.77 | L3MBTL1 (0.39) | USP2TDP1 | |
| SCHEMBL15416210 | 0.75 | ACVR1 (0.40) | CHRNB2CHRNA4IRAK4IKBKBHRH4 | |
| SCHEMBL31474530 | 0.74 | HRH4 (0.42) | CHRNB2CHRNA4IRAK4HRH4PRKD3 | |
| SCHEMBL26136470 | 0.73 | IKBKB (0.39) | CHRNB2CHRNA4IRAK4IKBKBHRH4 | |
| SCHEMBL7984894 | 0.72 | PARP1 (0.40) | CHRNB2CHRNA4HRH4ACVR1HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220127237-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MEDIBEACON INC. | 2022-04-28 | — | — | US | disclosed |
| US-10617687-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MEDIBEACON INC. (US) | 2020-04-14 | — | — | US | disclosed |
| US-20170298030-A9 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | Medibeacon, LLC | 2017-10-19 | — | — | US | disclosed |
| US-20160280665-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | Medibeacon, LLC | 2016-09-29 | — | — | US | disclosed |
| US-20160280666-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MEDIBEACON INC (US) | 2016-09-29 | — | — | US | disclosed |
| US-9376399-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MEDIBEACON LLC (US) | 2016-06-28 | — | — | US | disclosed |
| US-8778309-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MEDIBEACON LLC (US) | 2014-07-15 | — | — | US | disclosed |
| US-20140039191-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | Medibeacon, LLC (US) | 2014-02-06 | — | — | US | disclosed |
| EP-1854790-B1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | MALLINCKRODT INC (US) | 2011-08-31 | — | — | EP | disclosed |
| EP-1836175-B1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT INC (US) | 2010-04-28 | — | — | EP | disclosed |
| EP-2135863-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2009-12-23 | — | — | EP | disclosed |
| EP-2039688-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2009-03-25 | — | — | EP | disclosed |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | MALLINCKRODT INC. (US) | 2009-01-08 | — | — | US | disclosed |
| EP-1854790-A1 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | Mallinckrodt, Inc. (US) | 2007-11-14 | — | — | EP | disclosed |
| EP-1836175-A2 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT, INC. (US) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006071759-A2 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | MALLINCKRODT INC. (US) | 2006-07-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220127237-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, XDH, CYP4F12 | CHRNB2 3238/4885CHRNA4 2058/4885HRH1 677/4885 |
| US-10617687-B2 | Fluorescent pyrazine derivatives and methods of using the same in assessing renal function | GLS, CYP4F12, XDH | CHRNB2 3181/4885CHRNA4 2131/4885HRH1 556/4885 |
| US-20160280665-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, CYP4F12, XDH | CHRNB2 3181/4885CHRNA4 2131/4885HRH1 556/4885 |
| US-20160280666-A1 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, CYP4F12, XDH | CHRNB2 3181/4885CHRNA4 2131/4885HRH1 556/4885 |
| US-20170298030-A9 | FLUORESCENT PYRAZINE DERIVATIVES AND METHODS OF USING THE SAME IN ASSESSING RENAL FUNCTION | GLS, CYP4F12, XDH | CHRNB2 3181/4885CHRNA4 2131/4885HRH1 556/4885 |
| US-20090010851-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | GLS, CYP4F12, XDH | CHRNB2 3181/4885CHRNA4 2131/4885HRH1 556/4885 |
| US-20140039191-A1 | Fluorescent Pyrazine Derivatives and Methods of Using the Same in Assessing Renal Function | GLS, CYP4F12, XDH | CHRNB2 3181/4885CHRNA4 2131/4885HRH1 556/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.